Abstract. Dihydropyrimidine dehydrogenase (DPD) acts as the first-step enzyme catabolizing pyrimidines in vivo. DPYD gene mutations interfere with the breakdown of uracil and thymine. Genetic variations of DPYD can cause an enzyme deficiency state, which results in severe toxicity or other adverse side effects such as DNA damage or RNA damage caused by imbalance of the nucleotide pool. Our case-control study investigates the possible association between seven DPYD gene polymophisms (rs1801267, rs72547602, rs1801160, rs3918290, rs1801159, rs1801158, rs1801265) and risk of colorectal cancer (CRC). The association analysis for DPD was performed on 273 CRC patients and 187 healthy controls. There is significant allele association of SNP rs1801160 with colorectal cancer (p = 0.003, OR = 3.264, 95% CI = 1.425-7.475) in present analysis. Haplotype analysis of four DPYD polymorphisms showed significant difference in the distribution "IISt" haplotype between cases and controls. In comparison to the most common haplotype (VISt), the "IISt" haplotype was associated with increased risk for CRC (p = 0.038, OR = 2.733, 95% CI = 1.019-7.326). The present study suggests that the SNP rs1801160 and the "IISt" haplotype in the DPYD gene may also have a role in colorectal cancer risk.
Introduction
Colorectal cancer (CRC) is one of the most common malignance and the third leading cause of cancer death in world. Recent statistics have indicated that the Slovak Republic has one of the highest rates of CRC worldwide, and this applies particularly to Slovak males. Slovak male colorectal cancer incidence rates rank 1st in Europe, while female CRC incidence rates rank 5th in Europe. From the global perspective, CRC incidence and mortality rates have been highest in Central and West European countries. In 2012, Slovakia, Hungary, Denmark, Netherlands, and Czech Republic had the highest incidence rate of CRC among European countries (Ferlay et al. 2013) .
Population-based genetic association studies (case-control studies) are the most widely used studies of the impact of genetic variants on the risk of developing a particular complex disease. In this way, hundreds of association studies have been performed in order to elucidate the genetic contribution to complex diseases, such as cancer. These studies identified several low penetrance genes that behave as cancer risk modifiers, contributing to the understanding of tumor formation in many types of cancers and leading to advances in diagnosis and therapy.
Dihydropyrimidine dehydrogenase (DPD) is a regulatory enzyme in the pyrimidines catabolic pathway responsible for conversion of thymine or uracil to 5,6-dihydrothymine or 5,6-dihydrouracil, respectively. These intermediates are further metabolized to final products, β-alanine or β-aminoisobutyric acid, respectively. β-aminoisobutyric acid act as a rough indicator for rate of DNA turnover. DPD activity varies in human tissues. Its activity is especially high in hepatic cells and in peripheral blood mononuclear cells. Among Caucasian populations partial deficiency of DPD activity affects between 1% to 7% of people and its total loss is very rare, affecting about 0.2% of people. DPD deficiency is diagnosed by the accumulation of uracil and thymine and results in excess quantities of these molecules in the blood, urine, and cerebrospinal fluid (van Gennip and van Kuilenburg 2000; Maring et al. 2005) . The importance and difficulty of clinical recognition is underlined by the fact that pyrimidine defects can be the basis of unexplained anemia (megaloblastic, haemolytic or aplastic), delayed development, epilepsy, neonatal fitting, hyper-or hypotonicity, microcephaly, mental retardation, dysmorphic features, neurogastrointestinal symptoms, ophthalmoplegia, malabsorption, muscle atrophy, polyneuropathy, and toxic reactions to pyrimidine analogue drugs (van Gennip and van Kuilenburg 2000) .
Human dihydropyrimidine dehydrogenase (DPYD) gene is located on chromosome 1p21.3, encompassing 23 exons and spanning approximately 843 kb. More than 50 mutations in the DPYD gene have been identified and these mutations interfere with the failure of uracil and thymine metabolism. Genetic variations of DPYD can cause an enzyme deficiency, which could result in severe toxicity or other adverse side effects such as DNA or RNA damages caused by an imbalance of the nucleotide pool. Differences between various population groups as well as between individuals are expected. The incidence of DPD deficiency is reported to be 2.7% in patients with cancer, but partial DPD deficiency is more common affecting 12.3% of black women, 4.0% of black men, 3.5% of white women and 1.9% of white men (Saif 2013) .
Mutations in the DPYD gene have a dramatic effect on chemotherapy with drugs structurally similar to the pyrimidines (5-fluorouracil (5-FU), capecitabine). DPD deactivates more than 80% of standard doses of 5-FU. Some studies reported that DPD had the predictive value on sensitivity to 5-FU and prognostic value on long-term survival (Van Kuilenburg et al. 1999 , 2002 Ciccolini et al. 2006; Hammond et al. 2016) . Several DPYD variants (rs3918290, rs72547602, rs55886062, 67376798) are associated with risk for 5-FU toxicity, such as capecitabine or tegafur (Ezzeldin et al. 2004; Maring et al. 2005; Baskin et al. 2013) .
The aim of the present study was to investigate whether the distribution of the DPYD genotypes and haplotypes are over-represented in patients with sporadic CRC compare to healthy controls, and to establish whether these genotypes and haplotypes can be as a risk factor for CRC development in Slovak population.
Materials and Methods

Study subjects
A total of 273 patients with sporadic CRC were included in the study. The control group had 187 healthy unrelated volunteers. All subjects were Caucasians of European origin. Healthy donors had negative both past medical and family histories of CRC. Informed consent was obtained from all study subjects. This study was approved by the Human Subjects Committees at Jessenius Faculty in Medicine in Martin, Comenius University in Bratislava. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
DNA analysis
Genomic DNA was isolated from peripheral blood leukocytes by SiMaxTM Genomic DNA Extraction kit (Cat. No. CSC-50, SBS Genetech Co., Ltd., Beijing, China) according to the manufacturer's instructions. The dsDNA quantitation was conducted on common laboratory spectrophotometer according standard protocol (Barbas 2007) . DNA concentration was adjusted to 30 μg/ml and DNA was stored at -20°C for further analysis. All genotyping analyses were performed using high-resolution melting analysis (HRMA) on LightCycler® 480 II (Roche) using LightCycler® 480 High Resolution Melting Master (Cat. No. 04 909 631 001, Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. Designing of all required primer sequences (Table 1) was performed by Primer3Plus software (Untergasser 2012) . Conditions for all seven PCR reactions were as follows: initial denaturation at 95°C for 5 minutes, annealing temperature 58°C and elongation temperature 72°C, duration of all termocycling steps were 10 seconds and reactions were carried out in total 45 cycles with final extension 72°C for 4 minutes. In PCR reactions with 15 µl of reaction volume were the concentrations of primers 0.2 µM and of magnesium ions 3 mM. Amplifications were followed by high resolution melting analysis (HRMA) in temperature range 60-95°C. Lengths of amplicons and melting intervals are also shown in Table 1 . In all reactions, positive and negative controls were included. As a quality control, about 10% of all samples were repeated as blinded duplicates.
DPYD gene analysis
Seven single nucleotide polymorphisms (SNPs) of the DPYD gene, all except one within coding region, were genotyped. The splice site mutation rs3918290 localized in intron 14 is associated with rare recessive disorder dihydropyrimidine dehydrogenase deficiency (DPD) and we included it in the study (Van Kuilenburg et al. 1999) . The basic characteristics of analyzed SNPs are summarized in Table 1 with further details described elsewhere (Sherry et al. 2001; Cunningham et al. 2015) .
Statistics
For descriptive statistics and testing hypothesis SPSS 16 was used (SPSS Inc. Released 2007; SPSS for Windows, Version 16.0. Chicago, SPSS Inc.). Nonparametric Mann-Whitney test was used for testing the differences of age values between control and patient groups. Pearson's χ 2 test for contingency tables was used to test distribution of sex between control and patient groups.
Single marker analysis and haplotype analysis were done using SNP & Variation Suite v8.3 (Golden Helix, Inc., Bozeman, MT, www.goldenhelix.com). The Fisher's exact test was used to estimate a significance of deviation from Hardy-Weinberg equilibrium and to execute the basic allelic association. Pearson's χ 2 test for contingency tables was used to examine haplotype associations. A haplotype frequency was estimated using expectation-maximization (EM) algorithm. Adjusted association tests were performed by logistic regression with case/control status as the dependent variable, and age and sex as confounding variable in additive genetic model. For predictive modelling, stepwise format of logistic regression was used. p values less than 0.05 were considered statistically significant. Odds ratios (ORs) with 95% confidence intervals (CI) were used to assess genetic effect.
Results
The average age was of 65.18 ± 11.41 years in patient group and 45.60 ± 13.91 years in control group. There is statistical significant difference in age between studied groups (Z adj = 12.884; p < 5ˑ10 -6 Mann-Whitney test). There is statistical significant difference in representation women between CRC patients and healthy controls (41.0% and 69.0%, respectively; χ 2 = 34.779, p < 5ˑ10 -6 ). The adjustment for two variables (age and gender) was done in patient and healthy control to eliminate incorrect modeling association of results.
Allele associations
There are two mutations (rs1801267, rs72547602) present in NCBI dbSNP (build 139) that were not detected in our study. The only two CRC patients have heterozygous genotype for rs3918290, all other patients and controls have wild-type homozygous genotype for rs3918290. There is significant allele association of rs1801160 with CRC (p = 0.003, OR = 3.264, 95% CI = 1.425-7.475) in present analysis (Table 2) . 
Genotype associations
Under additive and dominant model, after adjusting for age and sex, there is significant genotype association of rs1801160 with CRC (p = 0.003, OR = 4.202, 95% CI = 1.489-11.854; p = 0.003, OR = 4.301, 95% CI = 1.506-12.27 respectively), too (Table 3) . Adjusted forward stepwise logistic regression, performed to found out the best predictive association model, confirmed the rs1801160 out of five SNPs as the predictive marker/regressor.
Haplotype associations
Six haplotypes with frequency more than 1% was estimated from four SNPs (in order rs1801160, rs1801159, rs1801158, rs1801265) ( Table 4 ). The minor "IISt" haplotype with frequency only 1.4% in healthy controls shown significant higher risk for occurrence in CRC patients (p = 0.038, OR = 2.733, 95% CI = 1.019-7.326) ( Table 4 ). The reduced haplotypes estimated from two SNPs (in order rs1801160, rs1801158) in linkage disequilibrium have one major haplotype "VS" with frequency more than 97% and significantly higher occurrence in healthy controls (p = 0.001, OR = 0.295, 95% CI = 0.142-0.614). The minor haplotype "IS" has shown significantly higher risk for occurrence in CRC patients (p = 0.004, OR = 3.217, 95% CI = 1.403-7.376) ( Table 4) . Haplotype trend regression, stepwise with forward selection and adjusted for sex and age, yielded statistically significant results for model with case-control status as independent variable, gender and age as covariates, and only "IS" haplotype as regressor (p = 0.003, OR = 17.656, 95% CI = 2.216-140.6) ( Table 5) .
Discussion
Genetic polymorphisms of pyrimidine metabolism enzymes have been reported to be associated with risk of cancer. It could be hypothesized that there is an association between the gene polymorphisms in DPYD and cancer risk, based on a few reports which have been published (Tanaka et al. 2005; Figueiredo et al. 2013; Kelemen et al. 2014) .
The results of our study suggested a potential role for inherited DPYD variation in pyrimidine metabolism with risk of colorectal cancer. In the present case-control study seven SNPs DPYD genes were tested. No individuals with variant in two SNPs (rs1801267, rs72547602) were observed in patient group in our study population. Frequency of another two SNPs (rs3918290 and rs1801158) was low (from 0% to 2%) in both control and case groups. Our hypothesis about association between pathogenic variants in DPYD gene and increased risk of CRC was confirmed for rare rs1801160 variant. More complex information about combined variability of four SNPs of DPYD gene comes from haplotype analysis. Haplotypes are more powerful discriminators than single SNP in disease association studies. Genetic linkage, the non-random association of alleles expressed in linkage disequilibrium (LD), reduces number of haplotypes against allele combinations (Clark 2004 ). In the studied cohorts, out of 16 theoretically possible, only 6 haplotypes with the occurrence above 1% were estimated using EM algorithm implemented in SVS 8. Three of them represented common haplotypes occurring in patients with frequency about 90%, another three had the frequency less than 5%. The rare "IISt" haplotype (1.4% in controls) comprises significant 2.7-fold higher risk to CRC. Two SNPs (rs1801160, rs1801158) are in strong LD, so we examined reduced haplotype construct only from this ones. Haplotype importance was confirmed by minor "IS" haplotype significantly predominant in CRC, while major "VS" haplotype significantly prevailed in controls. Minor "IS" haplotype with minor alleles on both, rs1801160 and rs1801158, could be a potential predictive marker for CRC.
Risk factors associated with CRC include familial and hereditary factors and environmental lifestyle -related risk factors and/or their interactions. Growing evidence suggests that an appreciable component of the genetic contribution to 'sporadic' colorectal cancer is due to large number of variants individually having small effects, thereby invoking the common disease-common variant paradigm for this type of cancer (Cheah 2009; Tenesa and Dunlop 2009) . Colorectal cancer has been extensively studied in the laboratory and the clinics. Due to available technologies, most of this research has been focused on genetic and epigenetic aspects. Abnormality and DPD deficiency can be identified by different genetic analyses and by determination of DPD levels in the peripheral blood mononuclear cells, respectively. Epigenetic modifications of the DPYD promoter region have been identified as one of the most important regulatory mechanisms of DPD enzymatic activity.
Somatic mutations of DPYD are associated with upregulation of pyrimidine degradation, nucleotide synthesis, and nucleic acid processing while salvage and nucleotide conversion is downregulated in human skin coetaneous melanoma (Lauren et al. 2016) . The relative importance of salvage versus de novo synthesis likely depends on the growth conditions and on the tissue specificity. Recently, it has been published that salvage pathways are very important for surviving and proliferation of cancer cells in colorectal cancers (Qi and Voit 2014) .
Cancer cells take advantage of distinct metabolic pathways promoting cellular proliferation or oncogenic progression (Boroughs and DeBerardinis 2015) . Lauren et al. (2016) showed a comprehensive view on how a hypermutated metabolic gene deregulates pyrimidine and nucleic acid synthesis and promotes malignant progression of melanoma.
SNPs, deletion mutations, splicing deficits, frameshift mutations and methylation of DPYD gene may be associated with partial or total loss of DPD activity (Johnson et al. 1997; Yu et al. 2006) . Based on the complexity of DPYD gene (23 exons), a lot of sequence variations could be associated with cancer progression (Ezzeldin et al. 2003; Ogura et al. 2005; van Kuilenburg et al. 2005) . So far, more than 130 genetic polymorphisms have been recorded in NCBI dbSNP in the coding, intronic and untranslated 3' and 5' regions of DPYD. Conditions resulting in a mutant DPYD allele include base substitutions, splicing deficits and frameshift mutations (Panczyk 2014; Lauren et al. 2015) . The most frequently observed variants are rs1801159, rs1801160, and rs1801265 at frequencies of 11.5-30%, 0.7-9%, and 2.9-13.7%, respectively, but data regarding to their effects on DPD activity are disputable. Moreover, most DPYD variants and phenotypic consequence are of very low frequency, and several studies did not find any individuals with these variants (Caudle et al. 2013) .
Nowadays, genetic polymorphisms of pyrimidine metabolism enzymes have been reported to be associated with higher risk of cancer, but the physiologic role of this enzyme in cancer cells is still unknown (Amstutz et al. 2011 ). Shaul et al. (2014 demonstrated that DPD plays an essential role in the epithelial-mesenchymal transition, providing one of the first indications for its function in cancer. However, there is a clear distinction between this function and the normal role of DPD in the liver. Recently, the association of DPYD variants rs11587873 and rs828054 with modulated risk of ovarian cancer (Kelemen et al. 2014) or malignant lymphoma (Figueiredo et al. 2013 ) has observed. The study of Tanaka et al. (2005) suggested that influence of DPYD Cys29Arg (rs1801265) posed only a limited risk for the six malignancies in Japanese.
In conclusion, this study suggests that rs1801160 and the "IISt" haplotype in the DPYD gene may also have a role in colorectal cancer risk in the Slovak population, indicating the importance of this gene involved in pyrimidine metabolism with respect to cancer risk. Further studies of incident case -control populations will be required to confirm this hypothesis. Studies of this association among other ethnic groups also remain to be done.
